Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29481989 | 1.00 | HTR2C (0.46) | HTR2CDRD2KDM1ARCOR1HTR2A | |
| SCHEMBL20063859 | 0.91 | HTR2C (0.49) | HTR2CDRD2KDM1AHTR2AHTR2B | |
| SCHEMBL28491550 | 0.91 | HTR2C (0.49) | HTR2CDRD2KDM1AHTR2AHTR2B | |
| SCHEMBL20063858 | 0.91 | HTR2C (0.49) | HTR2CDRD2KDM1AHTR2AHTR2B | |
| Hydrochloric Acid SCHEMBL21294710 | 0.90 | HTR2C (0.50) | HTR2CDRD2KDM1ARCOR1HTR2A | |
| Hydrochloric Acid SCHEMBL28517839 | 0.90 | HTR2C (0.50) | HTR2CDRD2KDM1ARCOR1HTR2A | |
| SCHEMBL21294957 | 0.83 | SCN9A (0.46) | HTR2CDRD2KDM1AHTR2AHTR2B | |
| SCHEMBL29481970 | 0.83 | SCN9A (0.46) | HTR2CDRD2KDM1AHTR2AHTR2B | |
| SCHEMBL31495941 | 0.81 | HTR2C (0.49) | HTR2CDRD2KDM1AHTR2AHTR2B | |
| SCHEMBL28495431 | 0.79 | SCN9A (0.44) | HTR2CSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263786-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | ASAH2, ACER2, PCSK9 | HTR2C 2475/4885DRD2 3912/4885KDM1A 4612/4885 |
| US-11028075-B2 | Therapeutic compounds and methods of use thereof | TRPV1, HCN4, TRPA1 | HTR2C 823/4885DRD2 2128/4885KDM1A 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.